Akari Therapeutics (AKTX) Times Interest Earned (2014 - 2026)
Akari Therapeutics (AKTX) posted quarterly Times Interest Earned of -$157.58 for Q1 2026, down 347.04% year-on-year from $63.79 in Q1 2025, and up 97.87% on a QoQ basis from -$7404.0 in Q3 2025.
Akari Therapeutics (AKTX) Times Interest Earned (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Times Interest Earned for 10 consecutive years, with -$157.58 the latest figure, recorded in Q1 2026.
- Quarterly Times Interest Earned fell 347.04% year-over-year to -$157.58 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$146.81 (down 3185.81% YoY) and the FY2025 annual result came in at -$0.27, up 23.98% from the prior year.
- Times Interest Earned rose to -$157.58 in Q1 2026 per AKTX's latest filing, from -$7404.0 in the prior quarter.
- Over the last five years, Times Interest Earned for AKTX reached as high as -$0.12 in Q4 2023 and fell as low as -$7404.0 in Q3 2025.
- A 4-year average of -$997.1 and a median of -$38.84 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2025 — Times Interest Earned slumped 17353.91% — and 2026, when it sank 347.04%.
- Year by year, Times Interest Earned stood at -$0.12 in 2023, then plunged by 3218.36% to -$4.0 in 2024, then plunged by 185069.42% to -$7404.0 in 2025, then jumped by 97.87% to -$157.58 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$157.58, -$7404.0, and -$31.19 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - | -157.58 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -157.58 |
| Sep 30, 2025 | -7,404.00 |
| Jun 30, 2025 | -31.19 |
| Mar 31, 2025 | -35.25 |
| Dec 31, 2024 | -4.00 |
| Sep 30, 2024 | -42.42 |
| Dec 31, 2023 | -0.12 |
| Jun 30, 2023 | -302.25 |
| Jun 30, 2021 | -1,082.50 |
| Jun 30, 2020 | -53.54 |
| Jun 30, 2019 | -125.59 |
| Mar 31, 2016 | -0.17 |
| Dec 31, 2015 | 0.19 |
| Sep 30, 2015 | -1.01 |
| Jun 30, 2015 | -502.11 |
| Mar 31, 2015 | -363.18 |
| Dec 31, 2014 | 514.74 |
| Sep 30, 2014 | -75.65 |